Key Takeaways:
- ZIVO Bioscience, Inc. collaborates with a global animal health company to start a 42-day study on coccidiosis in broiler chickens.
- The study aims to validate ZIVO’s non-antibiotic, immune-modulating product for coccidiosis prevention and treatment.
- It replicates real-world conditions to ensure the product’s effectiveness in commercial poultry production.
- Results are expected in September, potentially advancing the commercialization of ZIVO’s treatment.
- The study compares ZIVO’s product with ionophore-based treatments and a combination approach with a coccidiosis vaccine.
ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a biotech and agtech research and development company, has announced the initiation of a 42-day confirmatory study in collaboration with a global animal health company. The study aims to validate the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed to prevent and treat coccidiosis in broiler chickens.
Study Objectives
The new study aims to build upon previous trials by replicating real-world conditions to confirm the product’s effectiveness in commercial poultry production environments. Coccidiosis is a significant concern for the poultry industry, costing over $10 billion annually. Traditional treatments often rely on antibiotics and ionophores, which have not seen significant innovation in decades.
Industry Collaboration
John Payne, Chairman and CEO of ZIVO Bioscience, commented on the collaboration, stating, “We are delighted to support a global leader in animal health as they perform this confirmatory study, which holds potential to accelerate commercialization of our innovative treatment.” Payne highlighted the long-standing reliance on traditional treatments, adding, “This 42-day study is a significant step forward in our mission to provide sustainable, antibiotic-free solutions for the poultry industry.”
Study Design and Funding
The study, funded by the major animal health company, will focus on the health and productivity of the birds under typical industry conditions. It will compare the administration of ZIVO’s product with traditional ionophore-based treatments, as well as a combination approach with the coccidiosis vaccine. Results are expected in September, which could potentially pave the way for ZIVO’s product to enter the market.
Potential Impact
Payne expressed optimism about the study’s potential outcomes: “Our product represents a groundbreaking alternative designed to boost the immune response of broiler chickens without the adverse effects associated with legacy treatments. We are optimistic the results of this study will further support its market readiness.”
ZIVO Bioscience Latest News
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) is making significant strides in the Biotech/Agtech industry with its breakthrough in therapeutic, medicinal, and nutritional product candidates derived from proprietary algal cultures. The company recently announced a major milestone on July 28, 2023: the commercialization of its proprietary algal biomass as a food or food ingredient, introducing ZivolifeTM to the market. This marks ZIVO’s entry into the global algae food market and sets the stage for a potential revolution in sustainable, nutrient-dense whole foods.
On the 31st of May, 2023, Zivo Bioscience announced it had received an updated dossier from an independent scientific review panel reconfirming the “Generally Recognized As Safe” (GRAS) designation for its proprietary algal biomass. This designation allows Zivo’s algal biomass to be used as an ingredient in a defined range of foods and beverages for human consumption.
On April 6, 2023, John Payne, chairman, chief executive officer, and president of Zivo Bioscience, Inc. (NASDAQ: ZIVO), announced a $1 million unsecured loan for six months. The loan contains warrants to buy 390,000 shares of ZIVO common stock with a strike price of $2.91 per share, bears interest at a simple rate of 10%, and is repayable in full within six months with no penalties.
1 Comment